Cytomegalovirus (CMV) pp65 Specific T Cells Expanded From Mobilised Peripheral Blood Stem Cell (PBSC) Collections for Prophylactic Adoptive Immunotherapy  by Clancy, L. et al.
S212 Poster Session IMethods: Monocyte-derived dendritic cells (mo-DC) were used
to present antigens from 5 viruses to T cells of normal donors.
CMV, EBV and human adenovirus (HadV) antigens were pre-
sented by transfection of mo-DC with recombinant adenovirus
vectors containing CMV pp65 and EBV EBNA1, LMP1 and
LMP2a genes. mo-DC were infected with the live attenuated
VZV OKA strain and incubated with overlapping peptide mixes
covering the BKV proteins LTA, STA, VP1, VP2 and VP3. After
two weekly mo-DC stimulations the cell product was cultured in
IL-2 for 21 days.
Results: The final multi-virus cell products from 9 cultures in-
creased in cell number from baseline (mean increase was 9-fold),
were predominantly CD3 positive (mean 92% range 85 to 97%).
There was significant variation between individuals in CD4:8 ratio.
Mean CD8 was 39%, range 3 to 71%, and CD4 was 50% range 26
to 92%. The majority of cells expressed CD45RO1 (mean 87%).
Amean of 27% of cells retained expression of CD62L.The total per-
centage of antigen specific T cells as measured by cytokine produc-
tion ranged from 3 to 52% (mean 15%). This was composed of both
CD4 (mean 13%) and CD8 cells (mean 20%). The mean percent of
cells responding to each antigen was as follows: CMV 6.3%, EBV
3.7%, BKV 2.1%, VZV 13.9% and Hadv 1%. Fold increase in
MHC multimer positive cells compared to baseline was as follows:
CMVpp65 HLA-A2 NLV 1742-fold, CMVpp65 HLA-B7 TPR
1689-fold, EBV LMP2a HLA-A2 CLG 124-fold, EBV LMP2a
HLA-A2 FLY 180-fold. Cells were analysed for production of IL-
2, interferon-gamma and TNF. Single cells producing one, two
and all three cytokines were observed in response to stimulation
with all antigens.
Discussion: This method allows for the rapid production of T cells
specific for 5 viruses for use in adoptive immunotherapy postHSCT.
It is not HLA-dependent and is rapid thus potentially enhancing the
protection available to immunocompromised transplant recipients.
The use of antigen and reagent sources that are consistent
with Good Manufacturing Practice will allow for rapid clinical
translation.159
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Hematopoietic Stem Cell Transplantation is the treatment of
choice for many common malignancies. However, recipients are
susceptible to viral infections after transplant. Antiviral drugs can
be effective, but are toxic and can become drug-resistant. Another
option is the administration of virus-specific donor-derived cytotoxic
T lymphocytes (CTL). Using a chimeric adenovirus expressing the
immunodominant CMV antigen pp65 (Ad5f35pp65) to modify anti-
gen-presenting cells, we generated CTL specific for EBV,
CMVpp65 and Adenovirus (Multivirus-specific CTL) from healthy
donors. We have infused 26 patients with multivirus-specific CTL
and have shown protection against all 3 viruses in vivo without sig-
nificant toxicity. However, while all patients have been protected
against EBV and Adenovirus,. 10%of patients developedCMV re-
activation after CTL infusion, suggesting that targeting a single
CMV antigen may not be entirely protective. After solid organ
transplantation, IE-1-specific T cells were shown to be themost pro-
tective against CMV infection and after CMV vaccine, recipients
have a stronger and more robust IE-1 response when compared to
pp65. Therefore we sought to develop a GMP-compliant strategy
to generate CTL targeting twoCMV antigens (pp65 and IE-1) while
not losing the breadth of specificity to EBV and adenovirus. CTL
were generated by transducing monocytes (first stimulation) and
then EBV-LCL with an Ad5f35-IE-1-I-pp65 vector at subsequent
stimulations. Resultant T cells recognized CMV pp65 (mean:330;
median:273; range:47-995) and IE-1 (mean:154; median:154;
range:11-505), Adenovirus hexon (mean:189; median:153;range:30-465) and penton (mean:109; median:37 range:1-353), and
EBV-LCL(mean:79; median: 55 range:9-301) as measured by
IFN-g ELISPOT and pentamer analysis. CTL were also able to
lyse EBV, CMV, and adenovirus targets in cytotoxicity assays as
well as HLA-matched CMV AD169-infected allogeneic fibroblasts.
Importantly, the new multivirus-CTL recognize at least two anti-
gens per virus, in addition to recognizing a breadth of epitopes
within each antigen. In conclusion, we have developed a strategy
to expand multivirus CTL targeting at least 2 antigens from EBV,
CMV, and adenovirus thus increasing the breadth of the antiviral re-
sponse and have begun the process of translating this to the clinic to
improve immunity to CMV after transplantation.160
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We have conducted two trials of donor derived CMV specific T
cells given prophylactically to HSCT recipients. Our results suggest
this controls CMV reactivation without the need for antiviral ther-
apy. The cells in these trials were derived from blood collected prior
to receivingG-CSF for stem cell mobilisation. Patients with overseas
donors have been ineligible for this therapy due to the logistical com-
plexities of obtaining a separate blood donation. This could be re-
solved if CMV specific T cells could be expanded from HSC
collections. The aims of this study were to generate CMV specific
T cells from G-CSF mobilised PBSC harvests, to assess the pheno-
type and function of these cells, and to conduct a phase I study of
their safety as adoptive immunotherapy.
PBMCwere isolated from up to 1.5% (0.8-4ml) of eight mobilised
PBSC collections. Monocyte derived dendritic cells were transfected
with a vector encoding CMVpp65 and co-cultured with PBMC to
stimulate expansion of T cells. Cultures were re-stimulated after 7
days and continued for 14 days with the addition of IL-2. At the
end of culture, cell number increased by 9 to 29 fold (mean 19)
and consisted primarily of T cells (mean 96.8%). T cells were of
memory phenotype with variable expression of CD62L (mean
13.4%, 2-29.8%). 7 of 8 cultures contained more CD8 (mean
76%, 45-93.8%) than CD4 T cells (19.4%, 4.9-53.7%). We ob-
served up to a 2061 fold increase in cells recognising a HLA-A2 re-
stricted CMV epitope. Specificity towards this epitope accounted for
16.6%, 49% and 75% of CD8 T cells in three donors. Five cultures
assessed by 51Cr release assay exhibited negligible alloreactivity
against allogeneic HLA matched target cells (0-1.7% lysis at an ef-
fector to target E:T ratio of 20:1) but strong killing of pp65 pulsed
targets (68.4-97.5% lysis at E:T 20:1). Five patients have been re-
cruited for a Phase I trial of prophylactic CMV specific T cell adop-
tive transfer using cells expanded from haemopoietic stem cell
harvests. Three have received infusions of 2x107 T cells per m2
with no adverse reactions. Patient follow up will monitor CMV reac-
tivation and immune reconstitution. In summary, generation of
CMV specific T cells starting from a mobilised stem cell product ap-
pears feasible and safe. Use of the stem cell product is convenient and
brings the generation of virus specific T cells within an established
regulatory framework that will facilitate more disseminated use of
adoptive immunotherapy.161
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Reactivation of cytomegalovirus (CMV) is a major barrier to the
success of organ and allogeneic stem cell transplantation (alloSCT).
